グリクラジドの中国市場

調査会社China Research and Intelligence社が発行したリサーチレポート(データ管理コード:DATA8102365)
◆英語タイトル:Investigation Report on China's Gliclazide Market, 2018-2022
◆発行会社/調査会社:China Research and Intelligence
◆商品コード:DATA8102365
◆発行日:2018年9月
◆調査対象地域:中国
◆産業分野:製薬
◆ページ数:30
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール
◆販売価格オプション(消費税別)
Single UserUSD2,200 ⇒換算¥248,600見積依頼/購入/質問フォーム
EnterprisewideUSD3,300 ⇒換算¥372,900見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
China Research and Intelligence社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[グリクラジドの中国市場]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

DescriptionThe overweight population and the incidence of type 2 diabetes are growing in China as the economy develops, the population ages, and the lifestyle changes. The number of people with type 2 diabetes exceeded 110 million at the end of 2017, and is still rising.
Taken by mouth, Gliclazide is a second-generation sulfonylurea to treat diabetes by stimulating insulin secretion from pancreatic β-cells. It can protect pancreatic β-cells from the apoptosis caused by hyperglycemia, and prevent atherosclerosis (build-up of fatty deposits in the arteries) caused by type 2 diabetes.
Developed by French company Servier, Gliclazide (trade name: Diamicron) was first launched in France in 1972, and entered China in the 1980s. In China, at least 200,000 people with type 2 diabetes are taking Gliclazide every year.
In 1987, Tianjin Huajin Pharmaceutical Factory (now known as Tianjin Huajin Pharmaceutical Co., Ltd.) started cooperating with Servier and Tianjin Pharmaceutical Station to produce Gliclazide (Diamicron), a new drug to treat type 2 diabetes. With the support of Servier, the company has been taking the leading position on China’s Gliclazide market. Also dominating the market are Servier and Servier (Tianjin) Pharmaceutical Co., Ltd., the joint venture of Servier and Tianjin Huajin Pharmaceutical Co., Ltd.
According to CRI, the sales value of Gliclazide kept rising after the drug entered China, and exceeded CNY 200 million in 2017. It is expected that China’s Gliclazide market will continue to grow as the incidence of type 2 diabetes rises.

*** レポート目次(コンテンツ)***

Table of Contents
1 Relevant Concepts of Gliclazide
1.1 Indications for Gliclazide
1.2 Development History of Gliclazide in China
1.3 Governmental Approval of Gliclazide in China

2 Sales of Gliclazide in China, 2013-2017
2.1 Sales Value
2.1.1 Overall Sales Value
2.1.2 Sales Value by Region
2.2 Sales Volume
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Region
2.3 Sales of Gliclazide by Dosage Form in China, 2013-2017
2.3.1 Tablets
2.3.2 Capsules

3 Analysis on Major Gliclazide Manufacturers in China, 2013-2017
3.1 Analysis on Market Share of Major Gliclazide Manufacturers
3.1.1 Market Share by Sales Value
3.1.2 Market Share by Sales Volume
3.2 Servier
3.2.1 Enterprise Profile
3.2.2 Sales of Servier’s Gliclazide in China
3.3 Servier (Tianjin) Pharmaceutical Co., Ltd.
3.4 Tianjin Huajin Pharmaceutical Co. Ltd.
3.5 Nanchang Helioeast Pharmaceutical Co., Ltd.
3.6 Guilin Hwasun Pharmaceutical Co., Ltd.

4 Prices of Gliclazide in China, 2017-2018
4.1 Servier (Diamicron)
4.2 Servier (Tianjin) Pharmaceutical Co., Ltd. (Diamicron)
4.3 Tianjin Huajin Pharmaceutical Co. Ltd. (Diamicron)
4.4 Nanchang Helioeast Pharmaceutical Co., Ltd. (Hongxuyang)
4.5 Guilin Hwasun Pharmaceutical Co., Ltd. (Xieerping)

5 Prospect of China’s Gliclazide Market, 2018-2022
5.1 Forecast on Market Size
5.2 Forecast on Market Trend

Selected Charts
Chart Sales of Gliclazide in China, 2013-2017
Chart Sales Value of Gliclazide in Parts of China, 2013-2017
Chart Sales Volume of Gliclazide in China, 2013-2017
Chart Sales Value of Gliclazide Tablets in China, 2013-2017
Chart Sales Value of Gliclazide Capsules in China, 2013-2017
Chart Market Share of Top 5 Gliclazide Manufacturers by Sales Value in China, 2013-2017
Chart Profile of Servier
Chart Sales Value of Servier’s Gliclazide in China, 2013-2017
Chart Sales Value of Servier (Tianjin) Pharmaceutical Co., Ltd.’s Gliclazide in China, 2013-2017
Chart Sales Value of Servier Tianjin Huajin Pharmaceutical Co. Ltd.’s Gliclazide in China, 2013-2017
Chart Prices of Servier’s Gliclazide in Parts of China, 2017-2018
Chart Prices of Servier (Tianjin) Pharmaceutical Co., Ltd.’s Gliclazide in Parts of China, 2017-2018
Chart Prices of Tianjin Huajin Pharmaceutical Co. Ltd.’s Gliclazide in Parts of China, 2017-2018
Chart Governmental Approval of Gliclazide in China
Chart Forecast on Sales Value of Gliclazide in China, 2018-2012



*** レポートのキーワード ***

グリクラジド

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
  • 粘度指数向上剤の世界市場
    In this report, the global Viscosity Index Improvers market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K MT), revenue (M …
  • 重量計市場(~2019):イタリア
    The industry report Weighing Machine Market in Italy to 2019 - Market Size, Development, and Forecasts offers the most up-to-date market data on the actual market situation, and future outlook for weighing machines in Italy. The research includes historic market data from 2008 to 2014 and forecasts …
  • スポーツ自転車の世界市場2017-2021
    ABSTRACTAbout Sports Bicycle Bicycles that are made to be fast and easy to handle on mountainous, rocky terrains as well as on smooth surfaces such as roads are called sports bicycles. These bicycles are equipped with multiple gear and advanced break systems to help riders enhance their performance …
  • Cosmo Bio Co., Ltd. (3386):企業財務及びSWOT分析(医療業界)
    Summary This comprehensive SWOT profile of Cosmo Bio Co., Ltd. provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potent …
  • 世界及び中国のネビラピン市場2017
    The 'Global and Chinese Nevirapine Industry, 2012-2022 Market Research Report' is a professional and in-depth study on the current state of the global Nevirapine industry with a focus on the Chinese market. The report provides key statistics on the market status of the Nevirapine manufacturers and i …
  • BBQエプロン&ミットの世界市場2016
    The Global BBQ Aprons & Mitts Industry 2016 Market Research Report is a professional and in-depth study on the current state of the BBQ Aprons & Mitts industry. Firstly, the report provides a basic overview of the industry including definitions, classifications, applications and industry chain struc …
  • Bionomics Ltd の製品パイプライン分析2016
    Bionomics Ltd - Product Pipeline Review - 2016 Summary Global Markets Direct’s, ‘Bionomics Ltd - Product Pipeline Review - 2016’, provides an overview of the Bionomics Ltd’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under develop …
  • 世界のSDSチゼル市場2016
    Notes:Production, means the output of SDS Chisel Revenue, means the sales value of SDS Chisel This report studies SDS Chisel in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with production, price, revenue a …
  • 交通標識の世界市場:販売動向2017
    Notes:Sales, means the sales volume of Traffic Sign Revenue, means the sales value of Traffic Sign This report studies sales (consumption) of Traffic Sign in Global market, especially in United States, China, Europe and Japan, focuses on top players in these regions/countries, with sales, price, rev …
  • Zalicus Inc. (ZLCS)(製薬・医療分野):企業のM&A・提携動向
    Summary Zalicus Inc. (Zalicus) is a bio pharmaceutical company synergistic combination of drugs with a focus on the novel treatment of pain and inflammation conditions. Its portfolio comprises several in-house developed clinical-stage product candidates targeting pain, Z944, a T-type calcium channel …
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(DATA8102365 )"グリクラジドの中国市場" (英文:Investigation Report on China's Gliclazide Market, 2018-2022)はChina Research and Intelligence社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。